Welcome to our dedicated page for Unity Btech news (Ticker: UBX), a resource for investors and traders seeking the latest updates and insights on Unity Btech stock.
Unity Biotechnology, Inc. (historically Nasdaq: UBX, now quoted over‑the‑counter as UNBX) has generated a stream of news centered on its efforts to develop senolytic and senescence‑modulating therapeutics for age‑related diseases, particularly in ophthalmology. Company press releases emphasize UBX1325, an investigational BCL‑xL inhibitor being studied in diabetic macular edema (DME), and the broader scientific rationale for targeting senescent cells in retinal disease.
News coverage for UBX includes clinical trial milestones from the Phase 2 BEHOLD and Phase 2b ASPIRE studies in DME, where Unity has reported statistically significant and clinically meaningful improvements in vision in BEHOLD and non‑inferior visual acuity gains versus aflibercept at most time points in ASPIRE, along with a favorable safety and tolerability profile. Additional articles highlight scientific recognition, such as publication of BEHOLD results in NEJM Evidence and presentations at the Association for Research in Vision and Ophthalmology (ARVO) annual meetings.
Corporate updates are another major theme. Recent releases describe Unity’s revised operating plans, substantial reductions in force, and a strategic review to explore alternatives for advancing UBX1325 and other assets while reducing operational cash burn. Governance and leadership developments, including board appointments and executive hires in ophthalmology and clinical development, have also been featured.
Regulatory and financial disclosures reported in Unity’s news flow include quarterly and annual financial results, cash runway commentary, and communications about Nasdaq listing compliance, delisting actions, and the transition of trading to the OTC Pink Marketplace. More recent filings and related announcements focus on Unity’s Plan of Dissolution under Delaware law, the scheduling of a special stockholder meeting to vote on liquidation and dissolution, and the company’s expectation, as disclosed in its proxy statement, that there may be no amounts available for distribution to stockholders.
Investors and observers following UBX news can therefore track both the historical development of its senolytic ophthalmology programs and the subsequent shift toward asset monetization, delisting, and planned corporate dissolution.
UNITY Biotechnology [NASDAQ: UBX] announced the publication of Phase 2 BEHOLD study results for UBX1325 in diabetic macular edema (DME) patients in NEJM Evidence. The study demonstrated that selective clearance of senescent cells in the retina led to long-lasting vision improvements, with patients experiencing meaningful and sustained visual acuity enhancement for 1 year after a single injection.
The company is currently conducting a Phase 2b ASPIRE study comparing multiple doses of UBX1325 head-to-head with aflibercept. Topline 24-week and 36-week data was released on March 24, 2025, with complete 36-week data expected in Q2 2025.
UNITY Biotechnology (NASDAQ:UBX) has released its Q1 2025 financial results and provided updates on its Phase 2b ASPIRE study in diabetic macular edema (DME). The company's lead drug candidate, UBX1325 (foselutoclax), showed vision improvements comparable to aflibercept but did not meet the primary endpoint of statistical non-inferiority at weeks 20 and 24, though it achieved non-inferiority at week 36 based on interim data.
Financial highlights include:
- Cash position of $16.9M as of March 31, 2025 (down from $23.2M in December 2024)
- Net loss of $7.3M in Q1 2025 (increased from $5.8M in Q1 2024)
- Research and development expenses decreased to $2.9M (from $3.7M)
- General and administrative expenses increased to $4.0M (from $3.9M)
The company expects current cash reserves to fund operations into Q4 2025, with full 36-week trial data anticipated in Q2 2025.
UNITY Biotechnology (UBX) announced topline results from its Phase 2b ASPIRE clinical trial of UBX1325 in patients with diabetic macular edema (DME) who had poor vision despite prior anti-VEGF treatment.
Key findings show UBX1325-treated patients achieved vision gains of +5.2 letters at 24 weeks and +5.5 letters at 36 weeks, comparable to aflibercept. The treatment was non-inferior to aflibercept at 9 out of 10 time points but missed the primary endpoint at weeks 20-24 (88% confidence interval vs 90% required).
Notable results include:
- Better performance than aflibercept in patients with moderate disease severity
- Consistent vision gains in patients switching from aflibercept
- Favorable safety profile with no major adverse events
UBX1325, a novel BCL-xL inhibitor, targets senescent cells in diabetic retinal blood vessels. Complete 36-week data expected in Q2 2025.
UNITY Biotechnology (NASDAQ: UBX) has announced a virtual investor event scheduled for March 24, 2025, at 8:00 AM ET to discuss important data from their Phase 2b ASPIRE study. The event will present 24- and 36-week results evaluating UBX1325 in patients with Diabetic Macular Edema (DME).
The presentation will feature Dr. Robert Bhisitkul, a key opinion leader from UCSF School of Medicine, alongside company management. UBX1325, characterized as a potent BCL-xL inhibitor with senolytic mechanism of action, is being developed to potentially improve long-term visual outcomes. The event will conclude with a live Q&A session.
UNITY Biotechnology [NASDAQ: UBX] has appointed Dr. Yehia Hashad to its Board of Directors and science committee. Dr. Hashad, currently executive vice president of R&D and chief medical officer at Bausch + Lomb, brings over 25 years of ophthalmology and drug development expertise.
This strategic appointment comes as UNITY prepares for its Phase 2b ASPIRE 24-week data readout for UBX1325, a potential treatment for diabetic macular edema. Dr. Hashad's extensive experience includes overseeing 40+ pharmaceutical programs at Allergan Aesthetics and serving as global medical director for macular degeneration treatments at Novartis Pharma AG.
UNITY Biotechnology (NASDAQ: UBX) has reported its Q4 and full-year 2024 financial results. The company anticipates receiving 24-week topline data from its Phase 2b ASPIRE study for UBX1325 (foselutoclax) in diabetic macular edema (DME) in Q1 2025, followed by 36-week data in Q2 2025.
Financial highlights include:
- Cash position of $23.2 million as of December 31, 2024 (down from $43.2M in 2023)
- Full-year 2024 net loss of $26.0 million (improved from $39.9M in 2023)
- Q4 2024 net loss of $8.4 million (compared to $4.3M in Q4 2023)
- Research and development expenses decreased to $13.0 million in 2024 (from $20.1M in 2023)
- General and administrative expenses reduced to $15.5 million in 2024 (from $19.0M in 2023)
UNITY Biotechnology [NASDAQ: UBX] announced that its Compensation Committee has granted a stock-based award to its new Chief Medical Officer, Federico Grossi. The award consists of options to purchase 150,000 shares of UNITY common stock, granted on January 6, 2025. The grant was made under the UNITY 2020 Employment Inducement Incentive Plan, amended in March 2020, which aims to provide incentives for new hires in accordance with Nasdaq Stock Market Rule 5635(c)(4).
UNITY Biotechnology [NASDAQ: UBX] has appointed Federico Grossi, M.D., Ph.D., as chief medical officer. Dr. Grossi brings over 20 years of biotech industry experience, most recently serving as CMO at Apellis Pharmaceuticals where he led the development of SYFOVRE for geographic atrophy. His appointment comes at a important time as UNITY approaches the readout of topline 24-week results from its Phase 2b ASPIRE study of UBX1325 in diabetic macular edema (DME).
During his 13-year tenure at Apellis, Dr. Grossi oversaw clinical strategy and development programs across multiple therapeutic areas, leading to the approval and launch of EMPAVELI and SYFOVRE. He managed 10-15 concurrent studies from proof-of-concept through phase 3 clinical trials across global regions and built the medical affairs and safety functions.
FAQ
What is the current stock price of Unity Btech (UBX)?
What is the market cap of Unity Btech (UBX)?
